Poll Results

What percent of new drugs in the next 5 years will use alternative payment models like subscription plans or multi-year payment plans?

0%:   0%

1% to 5%:   82%

5% to 10%:   9%

10% to 20%:   9%

20% to 30%:   0%

How quickly will payer and EHR real time benefit checks be implemented?

6 months:  0%

1 year:  0%

2 years:  75.0%

3 years:  12.5%

4 years or more:  12.5%

Never:  0%

HHS has proposed altering the safe harbor for pharmaceutical rebates. When will the proposed POS rebates be implemented for Medicare Part D and Medicaid plans?

2020:  27.27%

2021:  9.09%

2022:  9.09%

2023:  18.18%

Never:  36.36%

CVS and Walgreens have announced they will carry CBD products in select states. How soon until we see CBD products in all retail chain pharmacies?

0-6 months: 23.08%

6-12 months: 30.77%

12-24 months: 30.77%

24+ months: 0.00%

Never: 15.38%

How will the HHS proposed rule changes to Medicare Part D and Medicaid drug rebate safe harbors impact pharmaceutical product net costs for PBMs?

Higher net costs after the implementation of the proposed rule: 50%

Lower net costs after the implementation of the proposed rule: 12.5%

No impact, net costs will be at the same levels as today: 37.5%

What is the likelihood brand pharmaceutical manufacturers will slow drug price increases in 2019 based on the Trump administration’s proposals?

Highly Likely: 0%

Likely: 12.5%

Unlikely: 75%

Highly Unlikely: 12.5%

Are there more challenges with the new lower priced Repatha NDC compared with the higher priced NDC?

Yes: 57.1%

No: 42.9%

Do you think brand manufacturer’s strategy to introduce a lower priced brand NDC of an existing product is going to expand in 2019?

Yes: 85.7%

No: 14.3%

Will there be a(n) ______ number of pharmaceutical product price changes in 2019 compared to 2018?

Increased:  63.64%

Decreased:  0.00%

Similar:  36.36%

Do you believe there are sufficient treatment options for HIV to warrant formulary exclusions?

Yes: 75%

No: 25%

Do you believe there are sufficient treatment options for Hemophilia to warrant formulary exclusions?

Yes: 71%

No: 29%

Do you believe there are sufficient treatment options for Hereditary Angioedema to warrant formulary exclusions?

Yes: 17%

No: 83%

How will state regulation and licensure of PBMs impact retail pharmacies? (select all that apply)

Improve pharmacy reimbursement rates:  5.88%

Add transparency to Rx reimbursement:  35.29%

Reduce PBM conflict of interests:  17.65%

Eliminate retrospective financial clawbacks:  17.65%

No impact:  11.76%

Reduce pharmacy reimbursement rates:  11.76%